<DOC>
	<DOCNO>NCT01399827</DOCNO>
	<brief_summary>The purpose study ) ass efficacy omega-3 fatty acid treatment Deficient Emotional Self-Regulation ( DESR ) among stimulant treat Attention Deficit Hyperactivity Disorder ( ADHD ) adult , b ) ass side effect profile omega-3 fatty acid treatment DESR among stimulant treat ADHD adult , c ) ass effect omega-3 fatty acid supplementation ADHD symptom associate feature stimulant treat ADHD adult , ) predict value fatty acid present RBC cell membrane . This study 12-week trial adult 18-55 year age ADHD symptom DESR .</brief_summary>
	<brief_title>Omega-3 Fatty Acid Supplementation ADHD Pharmacotherapy ADHD Adults With Deficient Emotional Self-Regulation Traits</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Amphetamine</mesh_term>
	<mesh_term>Dextroamphetamine</mesh_term>
	<mesh_term>Dexmethylphenidate Hydrochloride</mesh_term>
	<criteria>Inclusion Criteria 1 . Male female adult age 1855 year . 2 . A diagnosis childhood onset Attention Deficit Hyperactivity Disorder , accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) base clinical assessment . Childhood onset define accord establish research criterion , require onset two symptom inattentive impulsive/hyperactive trait age 12 . 3 . A score 24 Adult ADHD Investigator Symptom Report Scale ( AISRS ) , , individual stably treat medication approve Food Drug Administration ADHD , Clinical Global Impression ( CGI ) ADHD severity score great 4 ( `` moderately ill '' ) . Those subject treat traditional ADHD pharmacotherapy must stable , effective dose ( per clinician evaluation ) FDAapproved treatment ADHD least one month time enrollment . 4 . A Deficient Emotional Self Regulation ( DESR ) Tscore Behavior Rating Inventory Executive FunctionAdult Version ( BRIEFA ) Emotional Control Scale least 65 and/or score 99 DERS . Exclusion Criteria 1 . For subject treat ADHD time enrollment , history nonresponse intolerance methylphenidate adequate dos determine clinician . 2 . A history intolerance omega3 fatty acid determine clinician . 3 . Pregnant nursing female . 4 . Serious , unstable medical illness include hepatic , renal , gastroenterological , respiratory , cardiovascular , endocrinologic ( thyroid ) , neurologic ( seizure ) , immunologic , hematologic disease . 5 . Glaucoma . 6 . Clinically unstable psychiatric condition include suicidality , homicidality , bipolar disorder , psychosis , lifetime history clinically serious condition potentially exacerbate stimulant mania , psychosis . 7 . Tics family history diagnosis Tourette 's syndrome . 8 . Current ( within 3 month ) DSMIV criterion abuse dependence psychoactive substance nicotine . 9 . Allergies fish shellfish ; multiple adverse drug reaction . 10 . Any concomitant medication primarily central nervous system activity specify Concomitant Medication portion protocol . 11 . Current use Monoamine Oxidase ( MAO ) Inhibitor use within past two week . 12 . Investigator his/her immediate family ; define investigator 's spouse , parent , child , grandparent , grandchild .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>